Second-generation Drug-eluting Stents in Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1164 participants.

Also called NCT03321032

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,164 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03321032
Other papers using this trial's data
  • Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial European heart journal, 2022-03-31 DOI, PubMed 34735004, PMC8970998 In the PMC Open Access subset under CC BY-NC.
  • Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial Heart (British Cardiac Society), 2025-11-25 DOI, PubMed 40562528

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03321032. Randomized; double masking; primary purpose treatment. Start 2017-12-19 (actual); primary completion 2021-01-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Second-generation Drug-eluting Stents in Diabetes
Acronym
SUGAR
Condition
Diabetes Mellitus
Intervention (Device)
Polymer-free amphilimus-eluting stents
Intervention (Device)
Biolinx Polymer-based zotarolimus-eluting stents
Lead sponsor
Spanish Society of Cardiology (class: other)

Record details

Record id
cardio:ct-nct03321032
Content hash
827e53a2fec5961ad430dd735cf2aab39f5aff13545336cf814ee438b3d27f62